Investor Relations

Delivering value to our shareholders with utmost transparency and timely information.

At Mega Lifesciences public company limited

Investor Relations is responsible for delivering value to our shareholders by communicating all the necessary information on a regular basis.

Investment Highlights

Market leading own consumer health and pharmaceutical brands in fast growing developing markets.

FINANCIAL PERFORMANCE IN 9M22

Overall operating revenue
THB mn
(up by 8.6% YoY)
Gross profit
THB mn
representing 44.5% of operating revenue
SG&A expenses
THB mn
representing 26.8% of operating revenue
Reported net profit
THB mn
(up by 27.3% YoY)

Latest Documents

Read our recent and archived releases, Financial statements, Quarterly results, Presentations, Publications and One Reports.

Financial Statement
Quarter 3/2022
Download
MD&A
Quarter 3/2022
Download
Presentation and Webcast
The Opportunity Day Q3/2022
View Webcast Download
Form 56-1 One Report
Annual Report 2021
Download
Resource Center

SET Announcements

14 November 2022
Management Discussion and Analysis Quarter 3 Ending 30 Sep 2022
Read More
14 November 2022
Financial Performance Quarter 3 (F45) (Reviewed)
Read More
14 November 2022
Financial Statement Quarter 3/2022 (Reviewed)
Read More

IR Calendar

23
Feb
2023
FY22 earnings announcement

IR CONTACT

  • Mr. Manoj Gurbuxani (Primary contact)
  • Mr. Francis Rego
  • Ms. Sujintana Boonworapat
  • Ms. Laila Mitnoi (IR Co-ordinator)
  • Mr. Thomas Abraham
  • Mr. Vivek Dhawan
  • investor@megawecare.com
  • +66 2 769 4230